Singapore markets open in 4 hours 55 minutes

Imunon, Inc. (0HUZ.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.0600-0.3250 (-23.47%)
At close: 06:02PM BST
Full screen
Previous close1.3850
Open1.0600
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.0600 - 1.0600
52-week range0.4943 - 1.5300
Volume46
Avg. volume2,348
Market capN/A
Beta (5Y monthly)2.08
PE ratio (TTM)N/A
EPS (TTM)-3.9680
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

    DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform’s potential as a next-generation vaccine, announces that the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study of IMUNON’s proprietary PlaCCine® pl

  • GlobeNewswire

    Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

    LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held

  • Thomson Reuters StreetEvents

    Q1 2024 Imunon Inc Earnings Call

    Q1 2024 Imunon Inc Earnings Call